


AMENDMENTS TO THE CLAIMS

Please cancel claims 46 and 48, and add new claims 54-74. This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-53. (Canceled)

54. (New): A method of reducing blood pressure in a patient, the method comprising administering to the patient a therapeutically effective amount of an inhibitor of soluble epoxide hydrolase, wherein said inhibitor is a compound or a pharmaceutically acceptable salt thereof having a structure of:



wherein R¹ and R³ are each independently selected from the group consisting of C₁-C₂₀ substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, and heterocyclic,

wherein substituents for alkyl and cycloalkyl are selected from the group consisting of -halogen, -OR', -NR'R'', -SR', -OC(O)R', -C(O)R', -CO₂R', -CONR'R'', -OC(O)NR'R'', -NR''C(O)R', -NR'-C(O)NR''R''', -NR''C(O)₂R', -NH-C(NH₂)=NH, -NR'C(NH₂)=NH, -NH-C(NH₂)=NR', -S(O)R', -S(O)₂R', -S(O)₂NR'R'', -CN, -NO₂, =O, =NR', and =N-OR',

wherein substituents for aryl and heteroaryl are selected from the group consisting of -halogen, -OR', -NR'R'', -SR', -OC(O)R', -C(O)R', -CO₂R', -CONR'R'', -OC(O)NR'R'', -NR''C(O)R', -NR'-C(O)NR''R''', -NR''C(O)₂R', -NH-C(NH₂)=NH, -NR'C(NH₂)=NH, -NH-C(NH₂)=NR', -S(O)R', -S(O)₂R', -S(O)₂NR'R'', -CN, -NO₂, -R', -N₃, -CH(Ph)₂, perfluoro(C₁-C₄)alkoxy, and perfluoro(C₁-C₄)alkyl,

wherein R', R'' and R''' each independently refer to hydrogen, unsubstituted (C₁-C₈)alkyl and heteroalkyl, unsubstituted aryl, aryl substituted with 1-3 halogens, unsubstituted alkyl,

alkoxy or thioalkoxy groups, or aryl-(C₁-C₄)alkyl groups, thereby reducing blood pressure in the patient.

55. (New): The method of claim 54, wherein the patient is a human.

56. (New): The method of claim 54, wherein the patient has hypertension.

57. (New): The method of claim 54, wherein blood pressure reduction comprises a reduction in systolic blood pressure.

58. (New): The method of claim 54, wherein the patient has high normal blood pressure.

59. (New): The method of claim 54, wherein the patient is at risk for cardiovascular disease, renal disease or stroke.


60. (New): The method of claim 54, wherein the patient has cardiovascular disease or renal disease.

61. (New): The method of claim 54, wherein the inhibitor is administered orally.

62. (New): The method of claim 54, wherein the inhibitor inhibits soluble epoxide hydrolase with an IC₅₀ of less than 500 μ M.

63. (New): The method of claim 54, wherein the inhibitor inhibits soluble epoxide hydrolase with an IC₅₀ of less than 17.8 μ M.


64. (New): A method of reducing blood pressure in a patient, the method comprising administering to the patient a therapeutically effective amount of an inhibitor of soluble epoxide hydrolase, wherein said inhibitor is a compound or a pharmaceutically acceptable salt thereof having a structure of:



wherein R^1 and R^3 are each independently selected from the group consisting of $\text{C}_1\text{-C}_{20}$ substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, and heterocyclic, wherein at least one of R^1 and R^3 is selected from the group consisting of $\text{C}_1\text{-C}_{20}$ substituted or unsubstituted alkyl and cycloalkyl, thereby reducing blood pressure in the patient.

65. (New): The method of claim 64, wherein the patient is a human.
66. (New): The method of claim 64, wherein the patient has hypertension.
67. (New): The method of claim 64, wherein blood pressure reduction comprises a reduction in systolic blood pressure.
68. (New): The method of claim 64, wherein the patient has high normal blood pressure.
69. (New): The method of claim 64, wherein the patient is at risk for cardiovascular disease, renal disease or stroke.
70. (New): The method of claim 64, wherein the patient has cardiovascular disease or renal disease.
71. (New): The method of claim 64, wherein the inhibitor is administered orally.
72. (New): The method of claim 64, wherein the inhibitor inhibits soluble epoxide hydrolase with an IC_{50} of less than $500\text{ }\mu\text{M}$.
73. (New): The method of claim 64, wherein the inhibitor inhibits soluble epoxide hydrolase with an IC_{50} of less than $17.8\text{ }\mu\text{M}$.

74. (New): A method of reducing blood pressure in a patient, the method comprising administering to the patient a therapeutically effective amount of an inhibitor of soluble epoxide hydrolase, wherein said inhibitor is a compound or a pharmaceutically acceptable salt thereof having a structure of:



wherein R¹ and R³ are each independently selected from the group consisting of C₁-C₂₀ substituted or unsubstituted alkyl, cycloalkyl, aryl, acyl, and heterocyclic, wherein when R¹ is aryl, then R³ is other than heteroaryl and aryl, thereby reducing blood pressure in the patient.